(March 1, 2017, 1:15 PM EST) -- WASHINGTON, D.C. — A patented method of “arresting or regressing” penile fibrosis was erroneously deemed unpatentable as obvious, a divided Federal Circuit U.S. Court of Appeals ruled Feb. 28 in a victory for Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LAB) (Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center v. Eli Lilly and Company, No. 16-1518, Fed. Cir., 2017 U.S. App. LEXIS 3581)....